Advertisement
Advertisement
TNXP
Tonix Pharmaceuticals Holding Corp.
13.66
USDSponsored
+1.21
+9.72%
Aug 25, 15:59 UTC -4
Closed
After-Market
13.66
0.00
0.00%
TNXP Earnings Reports
Positive Surprise Ratio
TNXP beat 22 of 43 last estimates.
51%
Next Report
Date of Next Report
Nov 09, 2026
Estimate for Q3 26 (Revenue/ EPS)
$9.42M
/-$2.56
Implied change from Q2 26 (Revenue/ EPS)
-30.42%
/+4.92%
Implied change from Q3 25 (Revenue/ EPS)
+186.35%
/-28.69%
Tonix Pharmaceuticals Holding Corp. earnings per share and revenue
On Aug 10, 2026, TNXP reported earnings of -2.44 USD per share (EPS) for Q2 26, beating the estimate of -2.75 USD, resulting in a 11.29% surprise. Revenue reached 13.54 million, compared to an expected 7.88 million, with a 71.89% difference. The market reacted with a +4.66% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 3 analysts forecast an EPS of -2.56 USD, with revenue projected to reach 9.42 million USD, implying an increase of 4.92% EPS, and decrease of -30.42% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Altimmune, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.13
Actual
-$0.12
Surprise
+14.22%
Aquestive Therapeutics, Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.10
Actual
-$0.18
Surprise
-70.78%
ARS Pharmaceuticals, Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.50
Actual
-$0.63
Surprise
-25.40%
Journey Medical Corporation Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.02
Actual
-$0.01
Surprise
+56.33%
MediWound Ltd.
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.77
Actual
-$0.77
Surprise
+0.89%
PolyPid Ltd. Ordinary Shares
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.38
Actual
-$0.35
Surprise
+9.28%
Talphera, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.06
Actual
-$0.06
Surprise
+11.76%
Nektar Therapeutics
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$2.02
Actual
-$1.23
Surprise
+39.24%
Karyopharm Therapeutics Inc.
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$1.30
Actual
-$2.31
Surprise
-78.16%
Vyome Holdings, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.19
Actual
-$0.10
Surprise
+48.40%
FAQ
What were Tonix Pharmaceuticals Holding Corp.'s earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Tonix Pharmaceuticals Holding Corp. reported EPS of -$2.44, beating estimates by 11.29%, and revenue of $13.54M, 71.89% above expectations.
How did the market react to Tonix Pharmaceuticals Holding Corp.'s Q2 2026 earnings?
The stock price moved up 4.66%, changed from $12.03 before the earnings release to $12.59 the day after.
When is Tonix Pharmaceuticals Holding Corp. expected to report next?
The next earning report is scheduled for Nov 09, 2026.
What are the forecasts for Tonix Pharmaceuticals Holding Corp.'s next earnings report?
Based on 3
analysts, Tonix Pharmaceuticals Holding Corp. is expected to report EPS of -$2.56 and revenue of $9.42M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement